ATE550436T1 - Sensibilisierung von krebszellen für eine therapie unter verwendung von sina-zielgenen aus den chromosomenregionen 1p und 19q - Google Patents

Sensibilisierung von krebszellen für eine therapie unter verwendung von sina-zielgenen aus den chromosomenregionen 1p und 19q

Info

Publication number
ATE550436T1
ATE550436T1 AT10167455T AT10167455T ATE550436T1 AT E550436 T1 ATE550436 T1 AT E550436T1 AT 10167455 T AT10167455 T AT 10167455T AT 10167455 T AT10167455 T AT 10167455T AT E550436 T1 ATE550436 T1 AT E550436T1
Authority
AT
Austria
Prior art keywords
therapy
cancer cells
sensitization
identity
nucleic acid
Prior art date
Application number
AT10167455T
Other languages
English (en)
Inventor
Francois Berger
Laurent Pelletier
Jean-Paul Issartel
Sandra Boccard
Original Assignee
Univ Grenoble 1
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Grenoble 1 filed Critical Univ Grenoble 1
Application granted granted Critical
Publication of ATE550436T1 publication Critical patent/ATE550436T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT10167455T 2006-07-31 2007-07-23 Sensibilisierung von krebszellen für eine therapie unter verwendung von sina-zielgenen aus den chromosomenregionen 1p und 19q ATE550436T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06291241A EP1884569A1 (de) 2006-07-31 2006-07-31 Sensibilisierung von Krebszellen für eine Therapie unter der Verwendung von siNA gerichtet gegen Gene aus der 1p und 19q chromosomalen Region

Publications (1)

Publication Number Publication Date
ATE550436T1 true ATE550436T1 (de) 2012-04-15

Family

ID=37496566

Family Applications (2)

Application Number Title Priority Date Filing Date
AT10167455T ATE550436T1 (de) 2006-07-31 2007-07-23 Sensibilisierung von krebszellen für eine therapie unter verwendung von sina-zielgenen aus den chromosomenregionen 1p und 19q
AT07825533T ATE479751T1 (de) 2006-07-31 2007-07-23 Sensibilisierung von krebszellen für eine therapie unter verwendung von sina-zielgenen aus den chromosomenregionen 1p und 19q

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT07825533T ATE479751T1 (de) 2006-07-31 2007-07-23 Sensibilisierung von krebszellen für eine therapie unter verwendung von sina-zielgenen aus den chromosomenregionen 1p und 19q

Country Status (5)

Country Link
US (2) US7939653B2 (de)
EP (3) EP1884569A1 (de)
AT (2) ATE550436T1 (de)
DE (1) DE602007008918D1 (de)
WO (1) WO2008015577A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2212341A4 (de) * 2007-10-24 2011-09-21 Merck Sharp & Dohme Neue hiv-targets
EP2802674B1 (de) * 2012-01-11 2020-12-16 Ionis Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur modulation der ikbkap-aufspaltung
CN102911938B (zh) * 2012-08-03 2015-01-21 华侨大学 一种靶向抑制POLD1基因表达的siRNA序列
EP4570246A1 (de) * 2023-12-15 2025-06-18 Eberhard Karls Universität Tübingen Medizinische Fakultät Kombinationspräparate mit synergistischer wirkung gegen gliome

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070918A2 (en) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
EP1386004A4 (de) * 2001-04-05 2005-02-16 Ribozyme Pharm Inc Modulation der mit der entzündungsausbreitung und dem neuritenauswuchs assoziierten genexpression unter verwendung von technologien auf nukleinsäurebasis
EP1575519A2 (de) * 2002-05-17 2005-09-21 Board Of Regents, The University Of Texas System Therapien auf cd26-basis gegen krebs und immunkrankheiten
AU2003295600A1 (en) * 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
DE602004015064D1 (de) * 2003-01-06 2008-08-28 Wyeth Corp Zusammensetzungen und verfahren zur diagnose und behandlung von kolonkrebs
US20070207195A1 (en) * 2004-06-08 2007-09-06 Applied Genetics Incorporated Dermatics Genetic Screening for Polymorphisms in Human Genes that Increase or Decrease Sensitivity to Toxic Agents
CA2587411A1 (en) * 2004-11-17 2006-05-26 Protiva Biotherapeutics, Inc. Sirna silencing of apolipoprotein b

Also Published As

Publication number Publication date
US20100076054A1 (en) 2010-03-25
EP2064328B1 (de) 2010-09-01
WO2008015577A2 (en) 2008-02-07
US20110294867A1 (en) 2011-12-01
US8293886B2 (en) 2012-10-23
DE602007008918D1 (de) 2010-10-14
ATE479751T1 (de) 2010-09-15
EP1884569A1 (de) 2008-02-06
US7939653B2 (en) 2011-05-10
EP2336320A1 (de) 2011-06-22
EP2064328A2 (de) 2009-06-03
WO2008015577A3 (en) 2008-10-30
EP2336320B1 (de) 2012-03-21

Similar Documents

Publication Publication Date Title
Maruyama et al. Knocking down long noncoding RNAs using antisense oligonucleotide gapmers
CY1120292T1 (el) ΔΙΑΜΕΣΟΛΑΒΟΥΜΕΝΗ ΑΠΟ RNA ΠΑΡΕΜΒΟΛΗ ΑΝΑΣΤΟΛΗ ΤΗΣ ΓΟΝΙΔΙΑΚΗΣ ΕΚΦΡΑΣΗΣ ΧΡΗΣΙΜΟΠΟΙΩΝΤΑΣ ΒΡΑΧΥ ΠΑΡΕΜΒΑΛΛΟΜΕΝΟ ΝΟΥΚΛΕΪΚΟ ΟΞΥ (siNA)
TW200909577A (en) Single-chain circular RNA and method of producing the same
WO2006119266A3 (en) Human micrornas and methods for inhibiting same
BRPI0811170B8 (pt) oligonucleotídeos de rna e complexos de rna substituídos por hidroximetila
ATE526407T1 (de) Insektenresistenz durch inhibierung von genexpression
ATE528008T1 (de) Rnai-modulation von aha und ihre therapeutische verwendung
WO2012177949A3 (en) Compositions and methods for inhibition of expression of protein c (proc) genes
Okamura et al. Aminopyridinyl–pseudodeoxycytidine derivatives selectively stabilize antiparallel triplex DNA with multiple CG inversion sites
NO20083089L (no) Antimyosin Va siRNA og huddepigmentering
MX2009000654A (es) Medios para inhibir la expresion de la cinasa de proteina 3.
WO2010017319A3 (en) Nucleic acid compounds for inhibiting plk1 gene expression and uses thereof
CN113166750A (zh) 可编程的条件性sirna及其用途
CN106103818A (zh) 精细调节的超特异性核酸杂交探针
Micheli et al. Perylene and coronene derivatives binding to G-rich promoter oncogene sequences efficiently reduce their expression in cancer cells
ATE479751T1 (de) Sensibilisierung von krebszellen für eine therapie unter verwendung von sina-zielgenen aus den chromosomenregionen 1p und 19q
JP7465507B2 (ja) Ｓｔａｐｌｅ核酸を利用したタンパク質翻訳反応の抑制法
ES2940189T3 (es) Método para hibridar una molécula de ácido nucleico
WO2008109518B1 (en) Nucleic acid compounds for inhibiting wnt gene expression and uses thereof
Morihiro et al. Wavelength-selective light-triggered strand exchange reaction
Nadal et al. “Parallel” and “Antiparallel Tail‐Clamps” Increase the Efficiency of Triplex Formation with Structured DNA and RNA Targets
Salemme et al. Expression pattern of two paralogs of the PI/GLO-like locus during Orchis italica (Orchidaceae, Orchidinae) flower development
CN114585738A (zh) 用于治疗血小板减少症的核酸分子及其应用
WO2023224102A1 (ja) 新規Ｓｔａｐｌｅ核酸
Patutina et al. Search for oligonucleotides selectively binding oncogenic miR-21